Alx Oncology Holdings (ALXO) Non-Current Deffered Revenue (2019)
Alx Oncology Holdings (ALXO) reported Non-Current Deffered Revenue of $135000.0 for Q4 2019.
Alx Oncology Holdings (ALXO) Non-Current Deffered Revenue (2019) Analysis & Trends
Alx Oncology Holdings (ALXO) has 1 years of Non-Current Deffered Revenue data on file, last reported at $135000.0 in Q4 2019.
- For the quarter ending Q4 2019, Non-Current Deffered Revenue changed N/A year-over-year to $135000.0; the trailing twelve-month figure through Dec 2019 stood at $135000.0 (changed N/A YoY), and the FY2019 full-year result was $135000.0, changed N/A from the prior year.
- Non-Current Deffered Revenue held at $135000.0 in Q4 2019.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $135000.0 in Q4 2019 to a low of $135000.0 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Alx Oncology Holdings | 211.24 Mn | 211.24 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 135,000.00 |